Deferasirox Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0009/G 
This was an application for a group of variations. 
13/09/2023 
SmPC 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/939/2
Periodic Safety Update EU Single assessment - 
08/06/2023 
n/a 
PRAC Recommendation - maintenance 
02210 
deferasirox 
IA/0008 
B.II.b.4.a - Change in the batch size (including batch 
31/05/2023 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IB/0005/G 
This was an application for a group of variations. 
15/03/2023 
04/04/2023 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0007 
B.II.b.2.c.1 - Change to importer, batch release 
25/01/2023 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0003 
C.I.11.z - Introduction of, or change(s) to, the 
04/02/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0004 
B.II.e.5.a.2 - Change in pack size of the finished 
21/12/2021 
24/06/2022 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
31/08/2021 
24/06/2022 
PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
18/06/2021 
24/06/2022 
SmPC 
To extend the shelf-life of the finished product as packaged 
life of the finished product - As packaged for sale 
(supported by real time data) 
for sale from 24 months to 36 months. 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
